Tag: living-cells
-
FDA panel supports Novartis version of Amgen arthritis drug
Novartis AG's cheaper version of Amgen Inc's arthritis drug Enbrel is highly similar in potency and safety to the original and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. The panel voted 20-O that there is no clinically meaningful difference between Novartis's drug, a biologic made of…